ADAM17 and cancer: A300E, which is rapidly internalized and exhibits an IC50 of approximately 0.7 mg/mL against ADAM17, facilitates the targeted delivery of conjugated toxins into cancer cells (Yamamoto et al., 2012; Trad et al., 2013).